Liversil

LIVERSIL

According to the World Health Organization, diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Insulin is a hormone that regulates blood sugar. Hyperglycaemia, or raised blood sugar, is a common effect of uncontrolled diabetes and over time leads to serious damage to many of the body's systems, especially the nerves and blood vessels.

In 2014, 8.5% of adults aged 18 years and older had diabetes. In 2016, diabetes was the direct cause of 1.6 million deaths and in 2012 high blood glucose was the cause of another 2.2 million deaths. Between 2000 and 2016, there was a 5% increase in premature mortality from diabetes. In high-income countries the premature mortality rate due to diabetes decreased from 2000 to 2010 but then increased in 2010-2016. In lower-middle-income countries, the premature mortality rate due to diabetes increased across both periods.

Given the high prevalence of diabetes in our country, researchers in IMP started to explore traditional and modern databases to design herbal-based formulations to manage diabetes. Going through many preclinical and clinical trials, our collogues in Department of Pharmacology and Applied Sciences succeeded to develop a herbal formulation for treatment of diabetes type 2. LIVERSIL is an anti-diabetic supplement containing 240 mg of silymarin (the seed extract of Silybum marianum L.) in form of oral capsules. LIVERSIL has some other therapeutic indications including diabetes type 2, fatty liver, anti-oxidant, and Gall bladder disorders.